Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


07.10.2019

2 Ann Surg
4 Ann Surg Oncol
5 Anticancer Res
1 Br J Cancer
1 Breast Cancer
1 Breast Cancer (Auckl)
2 Breast Cancer Res Treat
10 Breast J
1 Cancer
1 Cancer Lett
1 Cancer Res
3 Clin Breast Cancer
2 Clin Cancer Res
1 CMAJ
1 Eur J Cancer
1 Eur J Surg Oncol
1 Gene
3 Int J Cancer
1 J Clin Oncol
2 Lancet Oncol
2 Oncol Rep
1 Oncology
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg

  1. GANESAN K, Choy BJK
    Comment on "Bariatric Surgery is Associated with Reduced Risk of Breast Cancer in Both Premenopausal and Postmenopausal Women".
    Ann Surg. 2019 Oct 1. doi: 10.1097/SLA.0000000000003607.
    PubMed     Text format    

  2. FEIGELSON HS, Caan B, Weinmann S, Leonard AC, et al
    Response to: Comment on "Bariatric Surgery is Associated with Reduced Risk of Breast Cancer in Both Premenopausal and Postmenopausal Women".
    Ann Surg. 2019 Oct 1. doi: 10.1097/SLA.0000000000003603.
    PubMed     Text format    


    Ann Surg Oncol

  3. VALERO MG, Zabor EC, Park A, Gilbert E, et al
    The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.
    Ann Surg Oncol. 2019 Sep 26. pii: 10.1245/s10434-019-07814.
    PubMed     Text format     Abstract available

  4. EUHUS DM
    Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ.
    Ann Surg Oncol. 2019 Sep 27. pii: 10.1245/s10434-019-07875.
    PubMed     Text format    

  5. WEISS A, Wong S, Golshan M, Freedman RA, et al
    Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Ann Surg Oncol. 2019 Sep 27. pii: 10.1245/s10434-019-07785.
    PubMed     Text format     Abstract available

  6. WARD WH, DeMora L, Handorf E, Sigurdson ER, et al
    Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer.
    Ann Surg Oncol. 2019 Sep 27. pii: 10.1245/s10434-019-07844.
    PubMed     Text format     Abstract available


    Anticancer Res

  7. DAMASKOS C, Garmpi A, Nikolettos K, Vavourakis M, et al
    Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Anticancer Res. 2019;39:5285-5296.
    PubMed     Text format     Abstract available

  8. RESTREPO DJ, Boczar D, Huayllani MT, Sisti A, et al
    Survival Disparities in Male Patients With Breast Cancer.
    Anticancer Res. 2019;39:5669-5674.
    PubMed     Text format     Abstract available

  9. OZAWA H, Sata A, Fukui R, Bun A, et al
    A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
    Anticancer Res. 2019;39:5653-5662.
    PubMed     Text format     Abstract available

  10. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Clinical Evaluation of Dynamic Monitoring of Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios in Primary Endocrine Therapy for Advanced Breast Cancer.
    Anticancer Res. 2019;39:5581-5588.
    PubMed     Text format     Abstract available

  11. MORGAN S, Amemiya Y, Slodkowska E, Lu FI, et al
    Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
    Anticancer Res. 2019;39:5345-5352.
    PubMed     Text format     Abstract available


    Br J Cancer

  12. JOSEPH C, Al-Izzi S, Alsaleem M, Kurozumi S, et al
    Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
    Br J Cancer. 2019 Sep 27. pii: 10.1038/s41416-019-0589.
    PubMed     Text format     Abstract available


    Breast Cancer

  13. ZALLOUM H, AbuThiab T, Hameduh T, AlBayyari S, et al
    Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Breast Cancer. 2019 Sep 26. pii: 10.1007/s12282-019-01011.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  14. MCELFISH PA, Su LJ, Lee JY, Runnells G, et al
    Mobile Mammography Screening as an Opportunity to Increase Access of Rural Women to Breast Cancer Research Studies.
    Breast Cancer (Auckl). 2019;13:1178223419876296.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  15. BLANCHETTE PS, Lam M, Richard L, Allen B, et al
    Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Breast Cancer Res Treat. 2019 Oct 1. pii: 10.1007/s10549-019-05430.
    PubMed     Text format     Abstract available

  16. WARDELL SE, Yllanes AP, Chao CA, Bae Y, et al
    Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy.
    Breast Cancer Res Treat. 2019 Sep 27. pii: 10.1007/s10549-019-05454.
    PubMed     Text format     Abstract available


    Breast J

  17. SANCHEZ AM, Franceschini G, D'Archi S, De Lauretis F, et al
    Results obtained with level II oncoplastic surgery spanning 20 years of breast cancer treatment: Do we really need further demonstration of reliability?
    Breast J. 2019 Sep 27. doi: 10.1111/tbj.13490.
    PubMed     Text format     Abstract available

  18. OBI E, Tom MC, Manyam BV, Grobmyer SR, et al
    Outcomes with intraoperative radiation therapy for early-stage breast cancer.
    Breast J. 2019 Sep 27. doi: 10.1111/tbj.13574.
    PubMed     Text format     Abstract available

  19. UPADHYAYA VS, Lim GH, Chan EYK, Fook-Chong SMC, et al
    Evaluating the preoperative breast cancer characteristics affecting the accuracy of axillary ultrasound staging.
    Breast J. 2019 Sep 27. doi: 10.1111/tbj.13635.
    PubMed     Text format     Abstract available

  20. NAVARRO LC, Falcao-Junior PC, de Rezende ASM, Vieira RADC, et al
    Occult breast cancer associated with lymph node microcalcifications.
    Breast J. 2019 Sep 28. doi: 10.1111/tbj.13630.
    PubMed     Text format    

  21. YILMAZ KB, Saydam M, Tokgoz S, Akinci M, et al
    A novel monitorization technique for nerve protection during axillary surgery of the breast cancer patients.
    Breast J. 2019 Sep 28. doi: 10.1111/tbj.13644.
    PubMed     Text format    

  22. TURKER S, Cilbir E, Yilmaz KB, Yetisgin E, et al
    Tumor-to-tumor metastasis: Breast cancer metastasis to lung cancer.
    Breast J. 2019 Sep 29. doi: 10.1111/tbj.13558.
    PubMed     Text format    

  23. TANG CYL, Lam WW, Tan PH, Xie W, et al
    Myoepithelial hyperplasia: A rare mimic of breast cancer on (18) F-FDG PET/CT.
    Breast J. 2019 Sep 28. doi: 10.1111/tbj.13643.
    PubMed     Text format    

  24. LAFORGA JB
    Lacrimal gland metastasis from invasive lobular carcinoma (ER(+) , PR(-) , Her-2(+) ) as the first manifestation of disseminated breast cancer.
    Breast J. 2019 Sep 28. doi: 10.1111/tbj.13640.
    PubMed     Text format    

  25. LEHRBERG A, Bensenhaver J
    A rare presentation of bilateral, synchronous male breast cancer.
    Breast J. 2019 Sep 27. doi: 10.1111/tbj.13639.
    PubMed     Text format     Abstract available

  26. SAKIN A, Sakalar T, Sahin S, Yasar N, et al
    Factors affecting survival and treatment efficacy in breast cancer patients with bone marrow metastasis.
    Breast J. 2019 Sep 27. doi: 10.1111/tbj.13647.
    PubMed     Text format    


    Cancer

  27. HALEY JS, Hibler EA, Zhou S, Schmitz KH, et al
    Dose-dependent effect of aerobic exercise on inflammatory biomarkers in a randomized controlled trial of women at high risk of breast cancer.
    Cancer. 2019 Sep 30. doi: 10.1002/cncr.32530.
    PubMed     Text format     Abstract available


    Cancer Lett

  28. ZOU H, Chen H, Zhou Z, Wan Y, et al
    ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.
    Cancer Lett. 2019 Sep 26. pii: S0304-3835(19)30484.
    PubMed     Text format     Abstract available


    Cancer Res

  29. KEHM RD, Genkinger JM, MacInnis RJ, John EM, et al
    Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: a cohort study of women selected for familial and genetic risk.
    Cancer Res. 2019 Oct 2. pii: 0008-5472.CAN-19-1847.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  30. FENN K, Maurer M, Lee SM, Crew KD, et al
    Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
    Clin Breast Cancer. 2019 Aug 29. pii: S1526-8209(19)30663.
    PubMed     Text format     Abstract available

  31. FREEDMAN RA, Gelman RS, Agar NYR, Santagata S, et al
    Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
    Clin Breast Cancer. 2019 Aug 22. pii: S1526-8209(19)30657.
    PubMed     Text format     Abstract available

  32. TAKAHASHI Y, Iwamoto T, Suzuki Y, Kajiwara Y, et al
    Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Clin Breast Cancer. 2019 Sep 9. pii: S1526-8209(19)30643.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  33. SJOSTROM M, Chang SL, Fishbane N, Davicioni E, et al
    ---Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1038.
    PubMed     Text format     Abstract available

  34. LEE O, Sullivan ME, Xu Y, Rodgers C, et al
    Selective progesterone receptor modulators in early stage breast cancer: a randomized, placebo-controlled Phase II window of opportunity trial using telapristone acetate.
    Clin Cancer Res. 2019 Sep 30. pii: 1078-0432.CCR-19-0443.
    PubMed     Text format     Abstract available


    CMAJ

  35. VOGEL L
    Hormone therapy study restokes debate over breast cancer risk.
    CMAJ. 2019;191:E1088-E1089.
    PubMed     Text format    


    Eur J Cancer

  36. DIAS AS, Almeida CR, Helguero LA, Duarte IF, et al
    Metabolic crosstalk in the breast cancer microenvironment.
    Eur J Cancer. 2019;121:154-171.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  37. KIM R, Kawai A, Wakisaka M, Sawada S, et al
    Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer.
    Eur J Surg Oncol. 2019 Sep 18. pii: S0748-7983(19)30812.
    PubMed     Text format     Abstract available


    Gene

  38. XIE W, Zhang H, Qin S, Zhang J, et al
    The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.
    Gene. 2019;720:144088.
    PubMed     Text format     Abstract available


    Int J Cancer

  39. BUCCHI L, Ravaioli A, Mancini S, Baldacchini F, et al
    Detection by screening introduces biases into survival estimates for luminal A-like breast cancer patients.
    Int J Cancer. 2019 Oct 1. doi: 10.1002/ijc.32697.
    PubMed     Text format    

  40. JOHANSSON ALV, Ursin G
    Reply to: "Detection by screening introduces biases into survival estimates for luminal A-like breast cancer patients".
    Int J Cancer. 2019 Oct 1. doi: 10.1002/ijc.32699.
    PubMed     Text format    

  41. CATTERALL R, Lelarge V, McCaffrey L
    Genetic Alterations of Epithelial Polarity Genes are Associated with Loss of Polarity in Invasive Breast Cancer.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32691.
    PubMed     Text format     Abstract available


    J Clin Oncol

  42. HOWIE LJ, Singh H, Bloomquist E, Wedam S, et al
    Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
    J Clin Oncol. 2019 Sep 27:JCO1802217. doi: 10.1200/JCO.18.02217.
    PubMed     Text format     Abstract available


    Lancet Oncol

  43. TAN AR, Wright GS, Thummala AR, Danso MA, et al
    Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30616.
    PubMed     Text format     Abstract available

  44. GOEL S, Tolaney SM
    CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30627.
    PubMed     Text format    


    Oncol Rep

  45. DAI X, Chen X, Hakizimana O, Mei Y, et al
    Genetic interactions between ANLN and KDR are prognostic for breast cancer survival.
    Oncol Rep. 2019 Sep 24. doi: 10.3892/or.2019.7332.
    PubMed     Text format     Abstract available

  46. AN G, Wu F, Huang S, Feng L, et al
    Effects of CCL5 on the biological behavior of breast cancer and the mechanisms of its interaction with tumorassociated macrophages.
    Oncol Rep. 2019 Oct 1. doi: 10.3892/or.2019.7344.
    PubMed     Text format     Abstract available


    Oncology

  47. FUJITA N, Enomoto Y, Inakami K, Yanagisawa T, et al
    Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Oncology. 2019 Oct 1:1-7. doi: 10.1159/000502910.
    PubMed     Text format     Abstract available


    PLoS One

  48. LI Y, Giorgi EE, Beckman KB, Caberto C, et al
    Association between mitochondrial genetic variation and breast cancer risk: The Multiethnic Cohort.
    PLoS One. 2019;14:e0222284.
    PubMed     Text format     Abstract available

  49. HALASZ LM, Patel SA, McDougall JA, Fedorenko C, et al
    Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries.
    PLoS One. 2019;14:e0222904.
    PubMed     Text format     Abstract available

  50. CHIGNOLA R, Sega M, Molesini B, Baruzzi A, et al
    Collective radioresistance of T47D breast carcinoma cells is mediated by a Syncytin-1 homologous protein.
    PLoS One. 2019;14:e0206713.
    PubMed     Text format     Abstract available

  51. WINSLOW S, Scholz A, Rappl P, Brauss TF, et al
    Macrophages attenuate the transcription of CYP1A1 in breast tumor cells and enhance their proliferation.
    PLoS One. 2019;14:e0209694.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: